A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease
This study has been completed.
First Posted: March 20, 2006
Last Update Posted: April 29, 2015
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 2008|
|Primary Completion Date:||May 2008 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Submission:||August 17, 2010|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP, Benjamin ER, Boudes PF. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Mol Genet Metab. 2013 May;109(1):86-92. doi: 10.1016/j.ymgme.2013.01.009. Epub 2013 Jan 26.